Unklare Lymphadenopathie mit Panzytopenie bei einer Patientin mit rezidivierenden Hypoglykämien

Zusammenfassung

Eine Patientin wurde aufgrund rezidivierender postprandialer Hypoglykämien nach Roux-en-Y-Magenbypass mit Diazoxid behandelt, nachdem eine Ernährungsumstellung keine Symptomlinderung erzielt hatte. Nach Eindosierung von Diazoxid mit guter Akutverträglichkeit wurde die Patientin entlassen. Eine Woche nach Therapieeinleitung kam es zu einer Lymphadenopathie und Panzytopenie. Es fanden sich keine Hinweise auf das Vorliegen eines Infekts. Nach Absetzen von Diazoxid sistierten die Beschwerden. Unser Fallbericht weist auf seltene unerwünschte hämatologische Arzneimittelwirkungen unter Diazoxid hin.

Abstract

A patient was admitted for the treatment of recurrent postprandial hypoglycaemia after Roux-en-Y gastric bypass. Diazoxide was initiated after dietary recommendations had failed to relieve symptoms. The patient was discharged after the drug was administered with good acute tolerance. One week after initiation of therapy she developed lymphadenopathy and pancytopenia. There was no clinical evidence of an infection. After discontinuing diazoxide, the symptoms subsided. Our case report describes rare haemotological adverse drug reactions under diazoxide.

Schlüsselwörter

Hypoglykämien - Diazoxid - Panzytopenie - Lymphadenopathie - bariatrische Chirurgie

Key words

hypoglycaemia - diazoxide - pancytopenia - lymphadenopathy - bariatric surgery

Publication History

Received: 04 January 2021

Accepted: 23 February 2021

Article published online:
13 May 2021

• Literatur

• 1 Jammah AA. Endocrine and metabolic complications after bariatric surgery. Saudi J Gastroenterol 2015; 269-277 DOI: 10.4103/1319-3767.164183.
• 2 Gletsu-Miller N. A successful nutritional therapy for postprandial hypoglycemia after bariatric surgery. Am J Clin Nutr 2019; 267-268 DOI: 10.1093/ajcn/nqz059.
• 3 Raverdy V, Baud G, Pigeyre M. et al Incidence and Predictive Factors of Postprandial Hyperinsulinemic Hypoglycemia After Roux-en-Y Gastric Bypass: A Five year Longitudinal Study. Ann Surg 2016; 878-885 DOI: 10.1097/SLA.0000000000001915.
• 4 Tharakan G, Behary P, Wewer AlbrechtsenNJ. et al Roles of increased glycaemic variability, GLP-1 and glucagon in hypoglycaemia after Roux-en-Y gastric bypass. Eur J Endocrinol 2017; 455-464 DOI: 10.1530/EJE-17-0446.
• 5 Gonzalez-Gonzalez A, Delgado M, Fraga-Fuentes MD. Use of diazoxide in management of severe postprandial hypoglycemia in patient after Roux-en-Y gastric bypass. Surg Obes Relat Dis 2013; 18-19 DOI: 10.1016/j.soard.2011.05.010.
• 6 Shantavasinkul PC, Torquati A, Corsino L. Post-gastric bypass hypoglycaemia: a review. Clin Endocrinol (Oxf) 2016; 3-9 DOI: 10.1111/cen.13033.
• 7 Smith EP, Polanco G, Yaqub A. et al Altered glucose metabolism after bariatric surgery: What's GLP-1 got to do with it?. Metabolism 2018; 159-166 DOI: 10.1016/j.metabol.2017.10.014.
• 8 Meier JJ, Butler AE, Galasso R. et al Hyperinsulinemic hypoglycemia after gastric bypass surgery is not accompanied by islet hyperplasia or increased beta-cell turnover. Diabetes Care 2006; 1554-1559 DOI: 10.2337/dc06-0392.
• 9 Ohrstrom CC, Worm D, Hansen DL. Postprandial hyperinsulinemic hypoglycemia after Roux-en-Y gastric bypass: an update. Surg Obes Relat Dis 2017; 345-351 DOI: 10.1016/j.soard.2016.09.025.
• 10 Malik S, Mitchell JE, Steffen K. et al Recognition and management of hyperinsulinemic hypoglycemia after bariatric surgery. Obes Res Clin Pract 2016; 10: 1-14 DOI: 10.1016/j.orcp.2015.07.003.
• 11 Berg P, McCallum R. Dumping Syndrome: A Review of the Current Concepts of Pathophysiology, Diagnosis, and Treatment. Dig Dis Sci 2016; 11-18 DOI: 10.1007/s10620-015-3839-x.
• 12 Bettini S, Belligoli A, Fabris R. et al Diet approach before and after bariatric surgery. Rev Endocr Metab Disord 2020; 297-306 DOI: 10.1007/s11154-020-09571-8.
• 13 Suhl E, Anderson-Haynes SE, Mulla C. et al Medical nutrition therapy for post-bariatric hypoglycemia: practical insights. Surg Obes Relat Dis 2017; 13: 888-896 DOI: 10.1016/j.soard.2017.01.025.
• 14 Tabarin A, Goichot B, French Endocrine S. Treatment: symptomatic treatment of hypoglycaemia. Ann Endocrinol (Paris) 2013; 196-199 DOI: 10.1016/j.ando.2013.05.009.
• 15 Wales J, Wolff F. Hematological side-effects of diazoxide. Lancet 1967; 53-64 DOI: 10.1016/s0140-6736(67)92461-0.
• 16 Koch-Weser J. Diazoxide. N Engl J Med 1976; 1271-1273 DOI: 10.1056/NEJM197606032942306.
• 17 Fachinformation. Proglicem® 25/100. Germany: MSD SHARP & DOHME GMBH; 2013
• 18 Nauck MA, Creutzfeldt W. Insulin-producing tumors and the insulinoma syndrome. In: Dayal Y. Hrsg. Endocrine Pathology of the Gut and Pancreas. Boca Raton: CRC press; 1991: 195-225
• 19 Wang C, Pang S, Jiang Q. et al Treatment with acarbose in severe hypoglycaemia due to late dumping syndrome. West Indian Med J 2013; 861-863 DOI: 10.7727/wimj.2012.266.
• 20 Moreira RO, Moreira RB, Machado NA. et al Post-prandial hypoglycemia after bariatric surgery: pharmacological treatment with verapamil and acarbose. Obes Surg 2008; 18: 1618-1621 DOI: 10.1007/s11695-008-9569-9.
• 21 Ohrstrom CC, Worm D, Hojager A. et al Postprandial hypoglycaemia after Roux-en-Y gastric bypass and the effects of acarbose, sitagliptin, verapamil, liraglutide and pasireotide. Diabetes Obes Metab 2019; 2142-2151 DOI: 10.1111/dom.13796.
• 22 Guseva N, Phillips D, Mordes JP. Successful treatment of persistent hyperinsulinemic hypoglycemia with nifedipine in an adult patient. Endocr Pract 2010; 16: 107-111 DOI: 10.4158/EP09110.CRR.
• 23 Abrahamsson N, Engstrom BE, Sundbom M. et al GLP1 analogs as treatment of postprandial hypoglycemia following gastric bypass surgery: a potential new indication?. Eur J Endocrinol 2013; 885-889 DOI: 10.1530/EJE-13-0504.
• 24 Craig CM, Liu LF, Deacon CF. et al Critical role for GLP-1 in symptomatic post-bariatric hypoglycaemia. Diabetologia 2017; 531-540 DOI: 10.1007/s00125-016-4179-x.
• 25 Meier JJ, Gethmann A, Gotze O. et al Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans. Diabetologia 2006; 452-458 DOI: 10.1007/s00125-005-0126-y.
• 26 Nauck MA, Kleine N, Orskov C. et al Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7–36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993; 741-744 DOI: 10.1007/BF00401145.
• 27 Juzgado D, Sanchez-Yague A. The Use of the Overstitch Beyond Bariatric Endoscopy: A Pictorial Description. Gastrointest Endosc Clin N Am 2020; 30: 173-185 DOI: 10.1016/j.giec.2019.08.009.
• 28 Nauck MA, Meier JJ. Diagnostic accuracy of an „amended“ insulin-glucose ratio for the biochemical diagnosis of insulinomas. Ann Intern Med 2012; 767-775 DOI: 10.7326/0003-4819-157-11-201212040-00004.
• 29 Gill GV, Rauf O, MacFarlane IA. Diazoxide treatment for insulinoma: a national UK survey. Postgrad Med J 1997; 640-641 DOI: 10.1136/pgmj.73.864.640.
• 30 Adachi J, Mimura M, Minami I. et al Thrombocytopenia induced by diazoxide in a patient with an insulinoma. Intern Med 2014; 759-762 DOI: 10.2169/internalmedicine.53.1094.
• 31 Samols E, Marks V. The treatment of hypoglycaemia with diazoxide. Proc R Soc Med 1966; 59: 811-814
• 32 Bower BD, Rayner PH, Stimmler L. Leucine-sensitive hypoglycaemia treated with diazoxide. Arch Dis Child 1967; 410-415 DOI: 10.1136/adc.42.224.410.
• 33 Touati G, Poggi-Travert F, Ogier de Baulny H. et al Long-term treatment of persistent hyperinsulinaemic hypoglycaemia of infancy with diazoxide: a retrospective review of 77 cases and analysis of efficacy-predicting criteria. Eur J Pediatr 1998; 628-633 DOI: 10.1007/s004310050900.
• 34 Grosu D, Noel E, Andres E. Life-threatening pancytopenia associated with diazoxide. Eur J Intern Med 2004; 402 DOI: 10.1016/j.ejim.2004.06.007.
• 35 Wolff F, Hirsch E, Wales J. et al Experimental and clinical studies with diazoxide. Ann N Y Acad Sci 1968; 429-441 DOI: 10.1111/j.1749-6632.1968.tb19067.x.
• 36 Black J. Diazoxide and the treatment of hypoglycemia: an historical review. Ann N Y Acad Sci 1968; 194-203 DOI: 10.1111/j.1749-6632.1968.tb19045.x.
• 37 Ozon A, Demirbilek H, Ertugrul A. et al Anemia and neutropenic fever with high dose diazoxide treatment in a case with hyperinsulinism due to Munchausen by proxy. J Pediatr Endocrinol Metab 2010; 719-723 DOI: 10.1515/jpem.2010.23.7.719.
• 38 Komatsu Y, Nakamura A, Takihata M. et al Safety and tolerability of diazoxide in Japanese patients with hyperinsulinemic hypoglycemia. Endocr J 2016; 311-314 DOI: 10.1507/endocrj.EJ15-0428.
• 39 Yasuda A, Seki T, Kitajima N. et al A case of insulinoma effectively treated with low-dose diazoxide. Clin Case Rep 2020; 1884-1889 DOI: 10.1002/ccr3.3017.